# Oxbryta lawsuits

Pfizer withdrew Oxbryta (voxelotor), a sickle cell disease drug, from all markets on September 25, 2024, saying the data showed its benefit no longer outweighed its risk. [Pfizer, Sept. 25, 2024](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease) The federal panel that creates MDLs listed no Oxbryta docket in its November 2, 2026 report, and we found no settlement program in company or court sources. [JPML by district, Nov. 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-2-2026.pdf)

By Rachel Brown, Paralegal. Last checked: November 18, 2026. Canonical page: https://lawsuitloancompanies.com/mass-torts/oxbryta/

Key points:
- Pfizer announced the worldwide withdrawal of all lots of Oxbryta on September 25, 2024.
- The FDA said postmarketing trials showed more deaths and a higher rate of pain crises in patients taking Oxbryta than in those on placebo.
- On July 31, 2026, Pfizer told the FDA it was withdrawing its U.S. drug applications for Oxbryta.
- No Oxbryta MDL appears in the federal panel's November 2, 2026 list of pending dockets.

## What happened to Oxbryta

Pfizer announced on September 25, 2024 that it was withdrawing all lots of Oxbryta in every market where it was approved and stopping all active clinical trials and expanded access programs. The company said the data suggested an imbalance in vaso-occlusive crises, the pain episodes of sickle cell disease, and in fatal events. [Pfizer, Sept. 25, 2024](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease)

The Food and Drug Administration issued an alert the next day. It told health care professionals to stop prescribing Oxbryta and told patients and caregivers to contact their health care professional about stopping the drug and starting another treatment. [FDA, Sept. 26, 2024](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due)

- **FDA on deaths:** The FDA said there were more deaths in the Oxbryta group than in the placebo group in postmarketing studies. ([source](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due): "There were also more deaths in the Oxbryta treatment group as compared to the placebo group in these postmarketing studies.")
- **FDA on pain crises:** Pfizer reported a higher rate of vaso-occlusive crisis in patients receiving Oxbryta than in those on placebo. ([source](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due): "Pfizer reported a higher rate of vaso-occlusive crisis")
- **Approval history:** The FDA approved Oxbryta in 2019 through the accelerated approval pathway. ([source](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due): "FDA approved Oxbryta under the accelerated approval pathway in 2019")

The FDA extended the approval in 2021 to children ages 4 to 11. [FDA, Sept. 26, 2024](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due) If you or your child took Oxbryta and have not yet spoken with a doctor about the withdrawal, that conversation comes before any legal question.

## What has happened since the withdrawal

Pfizer's quarterly report filed on November 3, 2026 gives the latest company account. In Europe, the medicines regulator adopted a negative opinion on the drug's balance of benefit and risk in October 2025 and recommended that its marketing authorization stay suspended. [Pfizer Form 10-Q, Sept. 27, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm)

In July 2026, Pfizer met with the FDA about the agency's assessment of the data, and it was determined that there was no viable pathway for returning Oxbryta to the U.S. market. On July 31, 2026, Pfizer notified the FDA that it was voluntarily withdrawing its new drug applications. Pfizer also recorded a $525 million impairment charge on the drug. [Pfizer Form 10-Q, Sept. 27, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm)

None of this decides a lawsuit. A withdrawal is not a court finding that the drug injured a particular person, and each plaintiff would still have to prove that.

## Is there an Oxbryta MDL?

No Oxbryta MDL existed as of November 2, 2026. The Judicial Panel on Multidistrict Litigation's lists of pending dockets for that date, sorted by district and by size, include no docket for Oxbryta or voxelotor. [JPML by district, Nov. 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-2-2026.pdf) [JPML, Nov. 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-November-2-2026.pdf)

An MDL is created only when the panel decides that lawsuits pending in different federal districts share common questions of fact and should be handled together for pretrial proceedings. [28 U.S.C. 1407](https://www.law.cornell.edu/uscode/text/28/1407) Until that happens, each lawsuit moves on its own court's schedule.

No court or agency publishes a count of Oxbryta lawsuits, and we could not confirm from primary sources how many have been filed or where. Pfizer's November 2026 quarterly report does not mention Oxbryta injury lawsuits in its product litigation section. [Pfizer Form 10-Q, Sept. 27, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm) Statements about case counts on law firm websites are not official figures.

## Is there an Oxbryta settlement?

No Oxbryta settlement or claims program has been announced in the Pfizer filings, FDA statements and court lists we reviewed as of November 18, 2026. [Pfizer Form 10-Q, Sept. 27, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm) There are no official payout amounts, and anyone quoting a typical Oxbryta payout is estimating.

This litigation is at an early stage compared with the other mass torts on this site. The [mass tort overview](https://lawsuitloancompanies.com/mass-torts/) explains how cases usually move from filing to bellwether trials to settlement, and why that takes years.

## What this means for a lawsuit loan

Pre-settlement funding, also called a lawsuit loan, is an advance repaid only if you recover money. The Government Accountability Office says plaintiffs do not repay the funding if the lawsuit is not successful, and also that this funding is expensive. [GAO, 2022](https://www.gao.gov/assets/gao-23-105210.pdf)

No public data shows whether funders are advancing money on Oxbryta claims. With no MDL, no trial dates we could confirm and no settlement, there is little for a funder to price, and any advance could build up charges over a long and uncertain wait. [How lawsuit loans work](https://lawsuitloancompanies.com/guides/how-lawsuit-loans-work/) explains how those charges grow.

## What to ask your attorney

- Has my lawsuit been filed, and in which court?
- What is the deadline to file in my state, and when did the clock start?
- Which medical and pharmacy records show when I took Oxbryta and what happened afterward?
- Has anyone asked the federal panel to create an MDL, and how would that change my case?

## Sources

- [Pfizer, Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets (September 25, 2024)](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease): "the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population"
- [Food and Drug Administration, alert on the voluntary withdrawal of Oxbryta from the market due to safety concerns (September 26, 2024)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due): "Health care professionals should stop prescribing Oxbryta."
- [Pfizer Inc., Form 10-Q for the quarter ended September 27, 2026 (SEC)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm): "it was determined that there is no viable pathway for returning Oxbryta to market in the U.S."
- [Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by District, November 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-2-2026.pdf): "MDL Statistics Report - Distribution of Pending MDL Dockets by District"
- [Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by Actions Pending, November 2, 2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-November-2-2026.pdf): "MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending"
- [28 U.S.C. 1407, Multidistrict litigation (Legal Information Institute)](https://www.law.cornell.edu/uscode/text/28/1407): "When civil actions involving one or more common questions of fact are pending in different districts"
- [Government Accountability Office, Third-Party Litigation Financing: Market Characteristics, Data, and Trends, GAO-23-105210 (December 2022)](https://www.gao.gov/assets/gao-23-105210.pdf): "Plaintiffs do not have to repay the funding if their lawsuit is not successful."
